Table 1.
Theranostic agents approved for PCa in the 21st century
| International non-proprietary name (INN) | Brand name | Pharmacotherapeutic group | EMA approval date | FDA approval date | China NMPA approval date |
|---|---|---|---|---|---|
| Zoledronic acid | Zometa | Bone-targeting therapy | Mar 2001 | Feb 2002 | Dec 2018 |
| Degarelix | Firmagon | Endocrine therapy | Feb 2009 | Dec 2008 | July 2019 |
| Sipuleucel-T | Provenge | Immunotherapy | Sept 2013 | Apr 2010 | / |
| Cabazitaxel | Jevtana | Antineoplastic agents | Mar 2011 | Jun 2010 | / |
| Denosumab | Prolia/Xgeva | Bone-targeting therapy | July 2011 | Nov 2010 | May 2019 |
| Abiraterone | Zytiga | Endocrine therapy | Sept 2011 | Apr 2011 | Dec 2019 |
| Enzalutamide | Xtandi | Endocrine therapy | Jun 2013 | Aug 2012 | Nov 2019 |
| Radium-223 dichloride | Xofigo | Therapeutic radiopharmaceuticals | Nov 2013 | May 2013 | Aug 2020 |
| Fluciclovine (18F) | Axumin | Diagnostic radiopharmaceuticals | May 2017 | May 2016 | / |
| Pembrolizumab | Keytruda | Immunotherapy | / | May 2017 | / |
| Padeliporfin | Tookad | Antineoplastic agents | Sept 2017 | / | / |
| Darolutamide | Nubeqa | Endocrine therapy | Mar 2020 | Jul 2019 | Feb 2021 |
| Rucaparib | Rubraca | Antineoplastic agents | / | May 2020 | / |
| Olaparib | Lynparza | Antineoplastic agents | Nov 2020 | May 2020 | Jun 2021 |
| Relugolix | Orgovyx | Endocrine therapy | Mar 2022 | Dec 2020 | / |
| Piflufolastat F 18 | Pylarify | Diagnostic radiopharmaceuticals | / | May 2021 | / |
| Dostarlimab-gxly | Jemperli | Immunotherapy | / | Aug 2021 | / |
| 177Lu-PSMA-617 | Pluvicto | Therapeutic radiopharmaceuticals | / | Mar 2022 | / |
| 68Ga-PSMA-11 | Locametz | Diagnostic radiopharmaceuticals | / | Mar 2022 | / |